THE LANCET Infectious Diseases Vol 2 August 2002 http://infection.thelancet.com
1 Anderson RM, May RM. Infectious diseases of
humans: dynamics and control. Oxford: Oxford
University Press, 1991.
2 Macdonald GM. The epidemiology and control of
malaria. Oxford: Oxford University Press, 1957.
3 Blower SM, Small PM, Hopewell P. Control
strategies for tuberculosis epidemics: new models
for old problems. Science 1996; 273: 497–500.
4 Blower SM, Gerberding JLG. Understanding,
predicting and controlling the emergence of drug-
resistant tuberculosis: a theoretical framework.
J Mol Med 1998; 76: 624–36.
5 Lietman T, Porco TC, Dawson C, Blower SM.
Global elimination of trachoma: how frequently
should we administer mass chemotherapy? Nat
Med 1999; 5: 572–76.
6 Blower S, Koelle K, Kirschner D, Mills J. Live
attenuated HIV vaccines: predicting the trade-off
between efficacy and safety. Proc Natl Acad Sci USA
2001; 98: 3618–23.
7 Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual
transmission of an HIV-1 variant resistant to
multiple reverse-transcriptase and protease
inhibitors. N Engl J Med 1998; 339: 307–11.
8 Boden D, Hurley A, Zhang L, et al. HIV-1 drug
resistance in newly infected individuals. JAMA
1999; 282: 1135–41.
9 Little SJ, Daar ES, D’Aquila RT, et al. Reduced
antiretroviral drug susceptibility among patients
with primary HIV infection. JAMA 1999; 282:
10 Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L.
Transmission of antiretroviral drug-resistant HIV-
1 variants. Lancet 1999; 354: 729–33.
11 Salomon H, Wainberg MA, Brenner B, et al.
Prevalence of HIV 1 resistant antiretroviral drugs
in 81 individuals newly infected by sexual contact
or IDU. AIDS 2000; 14: F17–23.
12 Blower SM, Gershengorn HB, Grant RM. A tale of
two futures: HIV and antiretroviral therapy in San
Francisco. Science 2000; 287: 650–54.
13 Blower SM, Aschenbach AN, Gershengorn HB,
Kahn JO. Predicting the unpredictable:
transmission of drug-resistant HIV. Nat Med 2001;
14 Diekmann O, Heesterbeek JA, Metz JA. On the
definition and the computation of the basic
reproduction ratio R0 in models for infectious
diseases in heterogeneous populations. J Math Biol
1990; 28: 365–82.
15 Blower SM, McLean AR. Prophylactic vaccines,
risk behavior change and the probability of
eradicating HIV in San Francisco. Science 1994;
16 Catania JA, Morin SF, Canchola J, Pollack L,
Chang J, Coates TJ. U.S. priorities—HIV
prevention. Science 2000; 290: 717.
17 Blower SM, Dowlatabadi H. Sensitivity and
uncertainty analysis of complex models of disease
transmission: an HIV model, as an example. Inl
Stal Rev 1994; 2: 229–43.
18 Blower SM, Porco TC, Darby G. Predicting
and preventing the emergence of antiviral
drug resistance in HSV-2. Nat Med 1998; 4:
19 Iman RL, Helton JC, Campbell JE. An approach to
sensitivity analysis of computer models, part 1.
introduction, input variable selection and
preliminary variable assessment. J Qual Techn
1981; 13: 174–83.
20 Iman RL, Helton JC, Campbell JE. An approach to
sensitivity analysis of computer models, part 2.
ranking of input variables, response surface
validation, distribution effect and techniques
synopsis. J Qual Techn 1981; 13: 232–40.
21 Blower SM, McLean AR, Porco TC, et al. The
intrinsic transmission dynamics of tuberculosis
epidemics. Nat Med 1995; 1: 815–21.
22 Sanchez MA, Blower SM. Uncertainty and
sensitivity analysis of the basic reproductive rate:
tuberculosis as an example. Am J Epidemiol. 1997;
23 Gershengorn HB, Blower SM. The impact of
antivirals and the emergence of drug resistance:
HSV-2 epidemic control. AIDS Patient Care STDs
2000; 14: 133–42.
24 Huang W, De Gruttola V, Fischl M, et al. Patterns
of plasma human immunodeficiency virus type 1
RNA response to antiretroviral therapy. J Infect Dis
2001; 183: 1455–65.
25 Hansel A, Bucher HC, Nuesch R, Battegay MJ.
Reasons for discontinuation of first highly active
antiretroviral therapy in a cohort of proteinase
inhibitor-naive HIV-infected patients. J Acquir
Immune Defic Syndr 2001; 26: 191–93.
26 Gallant JE. Strategies for long-term success in the
treatment of HIV infection. JAMA 2000; 283:
27 Descamps D, Flandre P, Calvez V, et al.
Mechanisms of virologic failure in previously
untreated HIV-infected patients from a trial of
induction-maintenance therapy. JAMA 2000; 283:
28 Pialoux G, Raffi F, Brun-Vezinet F, et al.
A randomized trial of three maintenance regimens
given after three months of induction therapy
with zidovudine, lamivudine, and indinavir in
previously untreated HIV-1-infected patients.
N Engl J Med 1998; 339: 1269–76.
29 Havlir DV, Hellmann NS, Petropoulos CJ, et al.
Drug susceptibility in HIV infection after viral
rebound in patients receiving indinavir-containing
regimens. JAMA 2000; 283: 229–34.
30 Ghani AC, Henley WE, Donnelly CA, Mayer S,
Anderson RM. Comparison of the effectiveness of
non-nucleoside reverse transcriptase inhibitor-
containing and protease inhibitor-containing
regimens using observational databases. AIDS
2001; 15: 1133–42.
31 Paredes R, Mocroft A, Kirk O et al. Predictors of
virological success and ensuing failure in HIV-
positive patients starting highly active antiretroviral
therapy in Europe: results from the EuroSIDA
study. Arch Intern Med 2000; 160: 1123–32.
32 Iman RL, Helton JC, An investigation of
uncertainty and sensitivity analysis techniques for
computer models. Risk Anal 1988; 8: 71–90.
33 Kleijnen JPC, Helton JC. Statistical analyses of
scatter plots to identify important factors in large-
scale simulations, 1: review and comparison of
techniques. Reliability Engineering and System
Safety 1999; 65: 147–85.
34 HIV Seroepidemiology and Surveillance Section
AIDS Surveillance Unit. San Francisco annual
surveillance report 2000. San Francisco: San
Francisco Department of Public Health, 2001.
35 Quinn TC, Wawer MJ, Sewankambo N, et al. Viral
load and heterosexual transmission of human
immunodeficiency virus type 1. N Engl J Med 2000;
36 Velasco-Hernandez JX, Hsieh YH. Modelling the
effect of treatment and behavioral change in HIV
transmission dynamics. J Math Biol 1994; 32:
37 Hsieh YH, Velasco-Hernandez JX. Community
treatment of HIV-1: initial stage and asymptotic
dynamics. Biosystems 1995; 35: 75–81.
38 Centers for Disease Control. Increases in unsafe sex
and rectal gonorrhoea among men who have sex
with men—San Francisco, California, 1994–1997.
MMWR Morb Mortal Wkly Rep 1999; 48: 45–48.
39 Katz MH, Schwarz SK, Kellog TA, et al. Impact of
highly active antiretroviral treatment on HIV
seroincidence among men who have sex with men:
San Francisco. Am J Public Health 2002; 92:
40 Creese A, Floyd K, Alban A, Guiness L. Cost-
effectiveness of HIV/AIDS interventions in Africa:
a systematic review of the evidence. Lancet 2002;
41 Marseille E, Hofmann PB, Kahn JG. HIV
prevention before HAART in sub-Saharan Africa.
Lancet 2002; 359: 1851–56.
Eradicating HIV epidemics